English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

A great deal of information has been obtained on the system of growth hormone and IGF-1 in development of osteoporosis. The imbalance of this system may be the cause of diseases of neonatal period as well as disease associated with aging. In old age, the synthesis of IGF - 1 declines as well as the action of this peptide on tissues. The aim of this study is to find out the association between serum IGF-1 levels and bone mineral density. Sixty postmenopausal non osteoporotic women and sixty postmenopausal osteoporotic women were selected for this study. Out of 60 cases, 50 postmenopausal osteoporotic women completed the study. Bone mineral density (BMD) of postmenopausal women with symptom of osteoporosis was measured by ultrasonic bone densitometry (UBIS5000).Postmenopausal women with BMD results of T score ≤ - 2.5 were selected as cases and that of > - 1 were selected as controls. Serum IGF -1 level was measured by ELISA method after removal of IGFBP from IGF - 1. In this study, both base line BMD and serum IGF-1 level of the osteoporotic women were significantly lower than that of non osteoporotic women (p < 0.05). BMD and serum IGF-1 level in 3 months after calcitonin injection of osteoporotic women were significantly higher (p < 0.001) than that of baseline BMD and serum IGF-1 level. There was positive correlation between baseline serum IGF-1 and BMD level in postmenopausal osteoporotic women (r = 0.470, p = 0.001) as well as in control (r = 0.288, p= 0.025). It is hoped that this study will serve as ground for further study in the related fields, and thus, as part for the development of applications in the management of postmenopausal osteoporotic women.

Myanmar Experience with Serum IGF-1, Salmon Calcitonin and Postmenopausal Osteoporosis